AT395714B - Verfahren zur herstellung von neuen aromatischen heterocyclischen verbindungen - Google Patents
Verfahren zur herstellung von neuen aromatischen heterocyclischen verbindungen Download PDFInfo
- Publication number
- AT395714B AT395714B AT0271885A AT271885A AT395714B AT 395714 B AT395714 B AT 395714B AT 0271885 A AT0271885 A AT 0271885A AT 271885 A AT271885 A AT 271885A AT 395714 B AT395714 B AT 395714B
- Authority
- AT
- Austria
- Prior art keywords
- mmol
- mixture
- acid
- radical
- general formula
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 151
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 76
- 150000002148 esters Chemical class 0.000 claims description 62
- -1 alkyl radical Chemical class 0.000 claims description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 51
- 238000010992 reflux Methods 0.000 claims description 39
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 38
- 239000002253 acid Substances 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 34
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 150000003254 radicals Chemical class 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000008096 xylene Substances 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 238000005893 bromination reaction Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 claims description 5
- 230000031709 bromination Effects 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 239000003849 aromatic solvent Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 239000013067 intermediate product Substances 0.000 claims description 4
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 238000007239 Wittig reaction Methods 0.000 claims description 3
- 238000005917 acylation reaction Methods 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 199
- 239000000203 mixture Substances 0.000 description 169
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 111
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 74
- 239000003480 eluent Substances 0.000 description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 46
- 239000000243 solution Substances 0.000 description 43
- 239000000377 silicon dioxide Substances 0.000 description 36
- 239000000047 product Substances 0.000 description 32
- 239000007787 solid Substances 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 239000011521 glass Substances 0.000 description 28
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
- 235000019341 magnesium sulphate Nutrition 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 21
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 229940095102 methyl benzoate Drugs 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000004342 Benzoyl peroxide Substances 0.000 description 9
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 9
- 235000019400 benzoyl peroxide Nutrition 0.000 description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000004702 methyl esters Chemical class 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- MUGSXGBLOKGUAT-UHFFFAOYSA-N 3-hydroxy-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1O MUGSXGBLOKGUAT-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- URLJRTOPXKILMW-UHFFFAOYSA-N 2,4-dimethyl-3-sulfanylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1S URLJRTOPXKILMW-UHFFFAOYSA-N 0.000 description 3
- WNLMYNASWOULQY-UHFFFAOYSA-N 4-tert-butylbenzoyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)C=C1 WNLMYNASWOULQY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- RVBGDVQDQKGZLH-UHFFFAOYSA-N 3-(1-adamantyl)-4-decoxybenzoic acid Chemical compound CCCCCCCCCCOC1=CC=C(C(O)=O)C=C1C1(C2)CC(C3)CC2CC3C1 RVBGDVQDQKGZLH-UHFFFAOYSA-N 0.000 description 2
- MDRKJOPPZMFBCL-UHFFFAOYSA-N 3-(1-adamantyl)-4-methoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1C1(C2)CC(C3)CC2CC3C1 MDRKJOPPZMFBCL-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- CPWIUCQCJRWWTH-UHFFFAOYSA-N 5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 CPWIUCQCJRWWTH-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- PGBFYLVIMDQYMS-UHFFFAOYSA-N Methyl thiophene-2-carboxylate Chemical compound COC(=O)C1=CC=CS1 PGBFYLVIMDQYMS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- AVBKJILDUFRWKO-UHFFFAOYSA-N acetic acid;furan Chemical compound CC(O)=O.C=1C=COC=1 AVBKJILDUFRWKO-UHFFFAOYSA-N 0.000 description 2
- WBMKDDSMYHLQTN-UHFFFAOYSA-N acetic acid;thiophene Chemical compound CC(O)=O.C=1C=CSC=1 WBMKDDSMYHLQTN-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960002311 dithranol Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003659 hair regrowth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JNUZADQZHYFJGW-JOCHJYFZSA-N (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound FC=1C(=NC(=NC=1)NC1=C(C(=CC=C1)S(=O)(=O)C)F)C1=CNC2=C(C=CC=C12)NC([C@@H](COC)N1CCN(CC1)C)=O JNUZADQZHYFJGW-JOCHJYFZSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- YRQHDQYFWGODHS-UHFFFAOYSA-N 1-(5-bromo-2-decoxyphenyl)adamantane Chemical compound CCCCCCCCCCOC1=CC=C(Br)C=C1C1(C2)CC(C3)CC2CC3C1 YRQHDQYFWGODHS-UHFFFAOYSA-N 0.000 description 1
- SKIDNYUZJPMKFC-UHFFFAOYSA-N 1-iododecane Chemical compound CCCCCCCCCCI SKIDNYUZJPMKFC-UHFFFAOYSA-N 0.000 description 1
- BKYWPNROPGQIFZ-UHFFFAOYSA-N 2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1 BKYWPNROPGQIFZ-UHFFFAOYSA-N 0.000 description 1
- NYJXKHIVLGWPCF-UHFFFAOYSA-N 2-(1-adamantyl)-4-bromophenol Chemical compound OC1=CC=C(Br)C=C1C1(C2)CC(C3)CC2CC3C1 NYJXKHIVLGWPCF-UHFFFAOYSA-N 0.000 description 1
- YBCWQMCCLMMXNR-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-1-benzofuran-6-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC2=CC=C(C(O)=O)C=C2O1 YBCWQMCCLMMXNR-UHFFFAOYSA-N 0.000 description 1
- QEAHMFWPWFPKDV-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-1h-indole-6-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC2=CC=C(C(O)=O)C=C2N1 QEAHMFWPWFPKDV-UHFFFAOYSA-N 0.000 description 1
- RJNORCOINJYWSD-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NC2=CC=C(C(O)=O)C=C2N1 RJNORCOINJYWSD-UHFFFAOYSA-N 0.000 description 1
- PKGKOTXWXABJFB-UHFFFAOYSA-N 2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1-benzofuran-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2OC(C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC2=C1 PKGKOTXWXABJFB-UHFFFAOYSA-N 0.000 description 1
- VSZSQTFNGIIPGV-UHFFFAOYSA-N 2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=NC2=C1 VSZSQTFNGIIPGV-UHFFFAOYSA-N 0.000 description 1
- JLXGISLEMCPIIE-UHFFFAOYSA-N 2-(5-bromo-2-methoxyphenyl)adamantane Chemical compound COC1=CC=C(Br)C=C1C1C(C2)CC3CC2CC1C3 JLXGISLEMCPIIE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ZKIXVGOVWANWDU-UHFFFAOYSA-N 2-[4-methoxy-3-(2-methylundecan-2-yl)phenyl]-1-benzofuran-6-carboxylic acid Chemical compound C1=C(OC)C(C(C)(C)CCCCCCCCC)=CC(C=2OC3=CC(=CC=C3C=2)C(O)=O)=C1 ZKIXVGOVWANWDU-UHFFFAOYSA-N 0.000 description 1
- PNCWHIAZZSDHPU-UHFFFAOYSA-N 2-benzylsulfanylethanamine Chemical compound NCCSCC1=CC=CC=C1 PNCWHIAZZSDHPU-UHFFFAOYSA-N 0.000 description 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 1
- SJVKHZYVCVKEGM-UHFFFAOYSA-N 2-methylundec-1-ene Chemical compound CCCCCCCCCC(C)=C SJVKHZYVCVKEGM-UHFFFAOYSA-N 0.000 description 1
- LSYAGWWJTOTFQZ-UHFFFAOYSA-N 3,4-bis(aminomethyl)benzoic acid Chemical compound NCC=1C=C(C(=O)O)C=CC=1CN LSYAGWWJTOTFQZ-UHFFFAOYSA-N 0.000 description 1
- HEMGYNNCNNODNX-UHFFFAOYSA-N 3,4-diaminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1N HEMGYNNCNNODNX-UHFFFAOYSA-N 0.000 description 1
- PQBDMOAXTIEGDG-UHFFFAOYSA-N 3-(1-adamantyl)-4-[tert-butyl(dimethyl)silyl]oxybenzoic acid Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C(C(O)=O)C=C1C1(C2)CC(C3)CC2CC3C1 PQBDMOAXTIEGDG-UHFFFAOYSA-N 0.000 description 1
- WSEWBFJWBBOLCB-UHFFFAOYSA-N 3-(1-adamantyl)-N-(2-amino-5-methylphenyl)-4-methoxybenzamide Chemical compound NC1=C(C=C(C)C=C1)NC(C1=CC(=C(C=C1)OC)C12CC3CC(CC(C1)C3)C2)=O WSEWBFJWBBOLCB-UHFFFAOYSA-N 0.000 description 1
- OXASAUXTASIZPW-UHFFFAOYSA-N 3-amino-2,4-dimethylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(C)=C1N OXASAUXTASIZPW-UHFFFAOYSA-N 0.000 description 1
- QQHHCJGJRUZPAU-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-nitrobenzoic acid Chemical compound CC1=C(O)C([N+]([O-])=O)=CC=C1C(O)=O QQHHCJGJRUZPAU-UHFFFAOYSA-N 0.000 description 1
- WXQUGIVHDANZTM-UHFFFAOYSA-N 3-tert-butyl-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1C(C)(C)C WXQUGIVHDANZTM-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- BZFDFTINTDKDJF-UHFFFAOYSA-N 4-amino-3-hydroxy-2-methylbenzoic acid Chemical compound CC1=C(O)C(N)=CC=C1C(O)=O BZFDFTINTDKDJF-UHFFFAOYSA-N 0.000 description 1
- MJRUSXKALHWNDH-UHFFFAOYSA-N 4-bromo-2-tert-butyl-1-methoxybenzene Chemical compound COC1=CC=C(Br)C=C1C(C)(C)C MJRUSXKALHWNDH-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- DGRGLKZMKWPMOH-UHFFFAOYSA-N 4-methylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1 DGRGLKZMKWPMOH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010021197 Ichthyoses Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- WPUIGRPOKSXWGE-UHFFFAOYSA-N N-ethyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-benzoxazole-6-carboxamide Chemical compound C(C)NC(=O)C1=CC2=C(N=C(O2)C2=CC=3C(CCC(C=3C=C2)(C)C)(C)C)C=C1 WPUIGRPOKSXWGE-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000411545 Punargentus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- BAPQKUOLQDJQSN-UHFFFAOYSA-N diaminomethyl benzoate Chemical compound NC(N)OC(=O)C1=CC=CC=C1 BAPQKUOLQDJQSN-UHFFFAOYSA-N 0.000 description 1
- GDLBFKVLRPITMI-UHFFFAOYSA-N diazoxide Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- MNNMTFSPSVOWSF-UHFFFAOYSA-N dicyclohexylazanium;chloride Chemical compound Cl.C1CCCCC1NC1CCCCC1 MNNMTFSPSVOWSF-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- SLFLFNSLWZNOOG-UHFFFAOYSA-N ethanol;hydroiodide Chemical compound [I-].CC[OH2+] SLFLFNSLWZNOOG-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- OYBLYDGMPPILJI-UHFFFAOYSA-N glycerol radical Chemical compound OC[C](O)CO OYBLYDGMPPILJI-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- ZQLCWPXBHUALQC-UHFFFAOYSA-N hydroxytoluic acid Natural products CC1=CC=C(C(O)=O)C=C1O ZQLCWPXBHUALQC-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 208000029443 keratinization disease Diseases 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- RXCFVYMIQCLNEX-UHFFFAOYSA-N methyl 2-(3-tert-butyl-4-methoxyphenyl)-1-benzofuran-6-carboxylate Chemical compound COC(=O)C=1C=CC2=C(OC(=C2)C2=CC(=C(C=C2)OC)C(C)(C)C)C=1 RXCFVYMIQCLNEX-UHFFFAOYSA-N 0.000 description 1
- OZLLISZNPDFCPZ-UHFFFAOYSA-N methyl 2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-benzothiazole-6-carboxylate Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(C1=NC3=CC=C(C=C3S1)C(=O)OC)=CC=2 OZLLISZNPDFCPZ-UHFFFAOYSA-N 0.000 description 1
- YCKMKFUPELBBFN-UHFFFAOYSA-N methyl 2-[3-(1-adamantyl)-4-decoxyphenyl]-1,3-benzoxazole-6-carboxylate Chemical compound COC(=O)C1=CC2=C(N=C(O2)C2=CC(=C(C=C2)OCCCCCCCCCC)C23CC4CC(CC(C2)C4)C3)C=C1 YCKMKFUPELBBFN-UHFFFAOYSA-N 0.000 description 1
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
- ZDIBYVMYXUDPGP-UHFFFAOYSA-N methyl 3-(3-tert-butyl-4-methoxybenzoyl)oxy-4-methylbenzoate Chemical compound COC(C1=CC(=C(C=C1)C)OC(C1=CC(=C(C=C1)OC)C(C)(C)C)=O)=O ZDIBYVMYXUDPGP-UHFFFAOYSA-N 0.000 description 1
- XJQMTKDGLSAAJU-UHFFFAOYSA-N methyl 3-[3-(1-adamantyl)-4-decoxybenzoyl]oxy-4-aminobenzoate Chemical compound COC(C1=CC(=C(C=C1)N)OC(C1=CC(=C(C=C1)OCCCCCCCCCC)C12CC3CC(CC(C1)C3)C2)=O)=O XJQMTKDGLSAAJU-UHFFFAOYSA-N 0.000 description 1
- GFKDINNLIYHHGD-UHFFFAOYSA-N methyl 4-[3-(1-adamantyl)-4-methoxybenzoyl]sulfanyl-4-methylcyclohexa-1,5-diene-1-carboxylate Chemical compound COC(C1=CCC(C=C1)(C)SC(C1=CC(=C(C=C1)OC)C12CC3CC(CC(C1)C3)C2)=O)=O GFKDINNLIYHHGD-UHFFFAOYSA-N 0.000 description 1
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- DYVILULWRUFZJS-UHFFFAOYSA-N n-cyclohexylcyclohexanamine;hypochlorous acid Chemical compound ClO.C1CCCCC1NC1CCCCC1 DYVILULWRUFZJS-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006016 ophthalmologic non-steroidal antiinflammatory agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 229960003070 tioxolone Drugs 0.000 description 1
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0042192A AT401514B (de) | 1984-09-19 | 1992-03-05 | Verfahren zur herstellung von neuen organischen säuren bzw. säurechloriden |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU85544A LU85544A1 (fr) | 1984-09-19 | 1984-09-19 | Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique |
Publications (2)
Publication Number | Publication Date |
---|---|
ATA271885A ATA271885A (de) | 1992-07-15 |
AT395714B true AT395714B (de) | 1993-02-25 |
Family
ID=19730321
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0271885A AT395714B (de) | 1984-09-19 | 1985-09-18 | Verfahren zur herstellung von neuen aromatischen heterocyclischen verbindungen |
AT0042192A AT401514B (de) | 1984-09-19 | 1992-03-05 | Verfahren zur herstellung von neuen organischen säuren bzw. säurechloriden |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0042192A AT401514B (de) | 1984-09-19 | 1992-03-05 | Verfahren zur herstellung von neuen organischen säuren bzw. säurechloriden |
Country Status (21)
Country | Link |
---|---|
US (3) | US4740519A (en]) |
JP (1) | JPH0784437B2 (en]) |
AR (1) | AR243504A1 (en]) |
AT (2) | AT395714B (en]) |
AU (2) | AU578310B2 (en]) |
BE (2) | BE903254A (en]) |
CA (2) | CA1256804A (en]) |
CH (2) | CH665841A5 (en]) |
DE (2) | DE3546907C2 (en]) |
DK (1) | DK169475B1 (en]) |
ES (1) | ES8608487A1 (en]) |
FR (1) | FR2570377B1 (en]) |
GB (3) | GB2164648B (en]) |
GR (1) | GR852270B (en]) |
IT (1) | IT1209663B (en]) |
LU (1) | LU85544A1 (en]) |
MX (1) | MX166783B (en]) |
NL (1) | NL192878C (en]) |
PT (1) | PT81132B (en]) |
SE (2) | SE461466B (en]) |
ZA (1) | ZA857158B (en]) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448006A (en) | 1981-05-28 | 1984-05-15 | Donn Incorporated | Grid ceiling structure and method of converting |
LU86258A1 (fr) * | 1986-01-21 | 1987-09-03 | Rech Dermatologiques C I R D S | Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
FR2603280B1 (fr) * | 1986-08-29 | 1988-10-28 | Cird | Nouveau compose marque au tritium, sa preparation et son application notamment dans la determination de l'affinite des retinoides pour leur recepteur cellulaire |
NZ223237A (en) * | 1987-01-22 | 1991-03-26 | Shiseido Co Ltd | Hair growth promoting agent and compositions |
US5149705A (en) * | 1987-03-13 | 1992-09-22 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity |
US5234926A (en) * | 1987-03-20 | 1993-08-10 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5602130A (en) * | 1987-03-20 | 1997-02-11 | Allergan | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5264578A (en) * | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
FR2614618B1 (fr) * | 1987-04-30 | 1989-07-07 | Cird | Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire |
LU87038A1 (fr) * | 1987-11-04 | 1989-06-14 | Oreal | Esters aromatiques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant |
KR0139216B1 (ko) * | 1988-04-11 | 1998-05-01 | 제임스 엠. 캐내지 | 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르 |
US5366986A (en) * | 1988-04-15 | 1994-11-22 | T Cell Sciences, Inc. | Compounds which inhibit complement and/or suppress immune activity |
US5173499A (en) * | 1988-04-15 | 1992-12-22 | T Cell Sciences, Inc. | Compounds which inhibit complement and/or suppress immune activity |
US5506247A (en) * | 1988-04-15 | 1996-04-09 | T Cell Sciences, Inc. | Compounds that inhibit complement and/or suppress immune activity |
DE3830054A1 (de) * | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
US5166170A (en) * | 1989-07-03 | 1992-11-24 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
US4992468A (en) * | 1989-07-26 | 1991-02-12 | Allergan, Inc. | Phenylethenyl compounds having retinoid-like activity |
US5068252A (en) * | 1989-07-26 | 1991-11-26 | Allergan, Inc. | Methods of using phenylethenyl compounds having retinoid-like activity |
US5399561A (en) * | 1989-09-19 | 1995-03-21 | Allergan, Inc. | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity |
US5183827A (en) * | 1989-09-19 | 1993-02-02 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5162546A (en) * | 1989-09-19 | 1992-11-10 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5053523A (en) * | 1989-09-19 | 1991-10-01 | Allergan, Inc. | Ethynyl-chroman compounds |
US5248777A (en) * | 1989-09-19 | 1993-09-28 | Allergan, Inc. | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
US5272156A (en) * | 1989-09-19 | 1993-12-21 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5175185A (en) * | 1989-12-29 | 1992-12-29 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity |
US5264456A (en) * | 1989-12-29 | 1993-11-23 | Allergan, Inc. | Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity |
US5006550A (en) * | 1989-12-29 | 1991-04-09 | Allergan, Inc. | Chroman esters of phenols and benzoic acids having retinoid-like activity |
US5013744B1 (en) * | 1989-12-29 | 1994-09-20 | Allegran Inc | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity |
US5202471A (en) * | 1990-02-06 | 1993-04-13 | Allergan, Inc. | Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity |
US5254692A (en) * | 1990-04-06 | 1993-10-19 | Bayer Aktiengesellschaft | 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines |
US5273739A (en) * | 1990-12-07 | 1993-12-28 | Jim Baral | Composition and treatment for darkening hair color |
AU648158B2 (en) * | 1991-02-13 | 1994-04-14 | Allergan, Inc. | Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity |
CA2105379A1 (en) * | 1991-03-26 | 1992-09-27 | Roshantha A. S. Chandraratna | Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity |
US5134159A (en) * | 1991-03-26 | 1992-07-28 | Allergan, Inc. | 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity |
US5869067A (en) * | 1991-05-15 | 1999-02-09 | Centre International De Recherches Dermatologiques Galderma (Cird Galderma) | Bi-aromatic compounds and pharmaceutical and cosmetic compositions |
FR2677020B1 (fr) * | 1991-05-31 | 1993-08-27 | Cird Galderma | Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique. |
US5326898A (en) * | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
EP0626955A1 (en) * | 1992-02-11 | 1994-12-07 | Allergan, Inc. | Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity |
US5324840A (en) * | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
EP0595150B1 (de) * | 1992-10-29 | 1996-07-31 | Hoechst Aktiengesellschaft | Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US6172115B1 (en) | 1993-02-11 | 2001-01-09 | Allergan Sales, Inc. | Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid |
US5399586A (en) * | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
US5344959A (en) * | 1993-05-18 | 1994-09-06 | Allergan, Inc. | Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity |
CA2117413C (en) * | 1993-07-30 | 2006-11-21 | Neil Geach | Herbicidal isoxazole-4-yl-methanone derivatives |
GB9317949D0 (en) * | 1993-08-28 | 1993-10-13 | Stevens Malcolm F G | Benzothiazole compounds |
US5874431A (en) * | 1993-08-28 | 1999-02-23 | Cancer Research Campaign Technology Limited | Benzazole compounds |
US5475022A (en) * | 1993-10-18 | 1995-12-12 | Allergan, Inc. | Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity |
US5426118A (en) * | 1993-12-30 | 1995-06-20 | Allergan, Inc. | [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity |
US5451605A (en) * | 1993-12-30 | 1995-09-19 | Allergan, Inc. | 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity |
US5470999A (en) * | 1993-12-30 | 1995-11-28 | Allergan, Inc. | Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity |
EP0669323B2 (de) * | 1994-02-24 | 2004-04-07 | Haarmann & Reimer Gmbh | Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren |
US5498755A (en) * | 1994-08-23 | 1996-03-12 | Chandraratna; Roshantha A. | Disubstituted aryl and heteroaryl imines having retinoid-like biological activity |
FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
US5618931A (en) * | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5534641A (en) * | 1994-12-29 | 1996-07-09 | Allergan | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5599967A (en) * | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
US5489584A (en) * | 1994-12-29 | 1996-02-06 | Allergan, Inc. | Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5556996A (en) * | 1994-12-29 | 1996-09-17 | Allergan | Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity |
US5543534A (en) * | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5514825A (en) * | 1994-12-29 | 1996-05-07 | Allergan, Inc. | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5618943A (en) * | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
FR2729854A1 (fr) | 1995-01-26 | 1996-08-02 | Oreal | Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique |
FR2731706B1 (fr) * | 1995-03-14 | 1997-04-11 | Cird Galderma | Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
US6025388A (en) * | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
US5616712A (en) * | 1995-05-16 | 1997-04-01 | Allergan | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity |
US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US6942980B1 (en) | 1995-09-01 | 2005-09-13 | Allergan, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
DE19532311A1 (de) * | 1995-09-01 | 1997-03-06 | Basf Ag | Benzoylderivate |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) * | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
AU7598596A (en) * | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
US5663357A (en) * | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5688957A (en) * | 1995-12-29 | 1997-11-18 | Allergan | (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity |
US20030219832A1 (en) * | 1996-03-11 | 2003-11-27 | Klein Elliott S. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
WO1997034869A1 (fr) * | 1996-03-18 | 1997-09-25 | Eisai Co., Ltd. | Derives de l'acide carboxylique a cycles fusionnes |
US5773594A (en) * | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5763635A (en) * | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US6555690B2 (en) * | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5747542A (en) * | 1996-06-21 | 1998-05-05 | Allergan | Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity |
US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5808124A (en) * | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
FR2750426B1 (fr) * | 1996-06-28 | 1998-08-07 | Cird Galderma | Nouveaux composes biaryles heterocycliques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique |
TR199900684T2 (xx) * | 1996-07-08 | 1999-07-21 | Galderma Research & Development, S.N.C. | Apoptoz uyar�c� adamantil t�revleri ve bunlar�n kansere kar�� maddeler olarak kullan�m�. |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US5760276A (en) * | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
US6037488A (en) * | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
EE04641B1 (et) * | 1998-05-05 | 2006-06-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Bensimidasoolid ja bensoksasoolid, nende kasutamine hingamisteede ja dermatooside raviks ette nähtud ravimite valmistamiseks ning neid sisaldav ravim |
SI1194425T1 (sl) | 1999-06-23 | 2005-12-31 | Sanofi Aventis Deutschland | Substituirani benzimidazoli |
US6313107B1 (en) | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
US6369225B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6380256B1 (en) | 2000-08-29 | 2002-04-30 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6252090B1 (en) | 2000-08-29 | 2001-06-26 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
ATE369854T1 (de) * | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
FR2833165B1 (fr) * | 2001-12-10 | 2004-07-30 | Oreal | Utilisation de derives hydroxyles de benzofurane pour inhiber la glycation, composition les comprenant et procede de traitement. |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2004093873A1 (en) * | 2003-04-17 | 2004-11-04 | Janssen Pharmaceutica, N.V. | 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer |
BRPI0507861A (pt) | 2004-02-20 | 2007-07-17 | Boehringer Ingelheim Int | inibidores de polimerase viral |
DE602005027739D1 (de) * | 2004-06-30 | 2011-06-09 | Janssen Pharmaceutica Nv | Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs |
CA2578529A1 (en) | 2004-08-18 | 2006-02-23 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
US8158136B2 (en) | 2004-08-18 | 2012-04-17 | L'oréal | Emulsification system for use in cosmetics |
WO2006037922A1 (fr) * | 2004-10-04 | 2006-04-13 | L'oreal | Composition cosmetique et/ou dermatologique pour peaux sensibles |
KR20060087386A (ko) * | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
FR2889057B1 (fr) * | 2005-08-01 | 2008-07-18 | Oreal | Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches |
US8076365B2 (en) | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
FR2889808B1 (fr) | 2005-08-17 | 2011-07-22 | Oreal | Utilisation de l'acide 8-hexadecene-1,16-dicarboxylique comme agent de soin destine a favoriser la cohesion de la couche cornee |
US7816348B2 (en) * | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
JP2011512164A (ja) | 2007-02-20 | 2011-04-21 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 皮膚内への治療物質の送達方法 |
FR2912651A1 (fr) | 2007-02-21 | 2008-08-22 | Oreal | Emulsion e/h pour le soin de la peau. |
FR2912917B1 (fr) | 2007-02-26 | 2012-05-18 | Oreal | Milieu conditionne et ses utilisations |
FR2918886B1 (fr) | 2007-07-17 | 2010-01-08 | Oreal | Utilisation d'au moins un extrait bacterien cultive sur eau thermale pour le traitement des peaux, muqueuses et cuirs chevelus sensibles |
FR2919501B1 (fr) * | 2007-08-02 | 2010-12-31 | Oreal | Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees |
WO2009018657A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
JP2010535155A (ja) * | 2007-08-03 | 2010-11-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼ阻害剤 |
FR2920304B1 (fr) * | 2007-09-04 | 2010-06-25 | Oreal | Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse. |
FR2920305B1 (fr) | 2007-09-04 | 2010-07-30 | Oreal | Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles. |
CA2697735C (en) * | 2007-09-04 | 2014-02-18 | L'oreal | Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin |
KR20100098534A (ko) | 2007-12-19 | 2010-09-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이러스 폴리머라제 억제제 |
FR2928542B1 (fr) | 2008-03-13 | 2011-12-09 | Oreal | Procede de maquillage des levres |
FR2940907B1 (fr) | 2009-01-15 | 2011-03-04 | Oreal | Composition cosmetique ou dermatologique, comprenant un retinoide, un compose non phosphate a base d'adenosine et un polymere semi-cristallin |
FR2942719B1 (fr) | 2009-03-04 | 2011-08-19 | Oreal | Utilisation de microorganismes probiotiques pour limiter les irritations cutanees |
WO2011010075A1 (fr) | 2009-07-24 | 2011-01-27 | L'oreal | Utilisation d'un derive d'acide jasmonique en tant qu'agent apaisant |
FR2953716B1 (fr) | 2009-12-16 | 2015-03-27 | Oreal | Kit de formulation d'un produit cosmetique |
FR2968952A1 (fr) | 2010-12-17 | 2012-06-22 | Oreal | Ester d'acide amine n-acyle a titre d'agent apaisant |
FR2981272A1 (fr) | 2011-10-14 | 2013-04-19 | Inneov Lab | Utilisation d'une composition orale comprenant un melange d'au moins un polyphenol, de zinc, et de vitamine c. |
WO2013153678A1 (en) | 2012-04-11 | 2013-10-17 | L'oreal | Self-standing cosmetic sheet |
FR2996135A1 (fr) | 2012-09-28 | 2014-04-04 | Inneov Lab | Composition orale pour renforcer la tolerance cutanee suite a une administration topique d'un compose retinoide. |
EP2789369B1 (en) | 2013-04-14 | 2018-06-06 | Symrise AG | A composition for lightening skin and hair |
EP2842607B1 (en) | 2013-09-02 | 2018-05-30 | Symrise AG | A skin and/or hair whitening mixture |
CN105555366B (zh) | 2013-09-22 | 2020-12-01 | 西姆莱斯股份公司 | 海马齿苋提取物及其应用 |
EP2853254B1 (en) | 2013-09-26 | 2017-11-08 | Symrise AG | A composition for lightening skin and/or hair |
EP2859883B1 (en) | 2013-10-13 | 2019-05-15 | Symrise AG | Active mixtures comprising acylated oligopeptides and troxerutin |
EP3062766A1 (en) | 2013-10-29 | 2016-09-07 | L'Oreal, S.A. | Use of mono ornithine ketoglutarate (mokg) |
WO2015188015A1 (en) | 2014-06-04 | 2015-12-10 | Haro Pharmaceutical Inc. | 18-20 member bi-polycyclic compounds |
EP3443950A1 (en) | 2014-07-30 | 2019-02-20 | Symrise AG | A fragrance composition |
EP3023090B1 (en) | 2014-11-21 | 2019-08-07 | Symrise AG | Compositions |
EP3045161A1 (en) | 2015-01-18 | 2016-07-20 | Symrise AG | Active compositions comprising 1,2-hexanediol and 1,2-octanediol |
EP3081207B1 (en) | 2015-04-16 | 2022-09-21 | Symrise AG | Use of a liposome composition |
US10391071B2 (en) | 2015-04-28 | 2019-08-27 | Cutech Srl | Compositions comprising valerian extracts |
EP3097905B1 (en) | 2015-05-28 | 2020-11-04 | Symrise AG | Cosmetic compositions |
EP3108941B1 (en) | 2015-06-23 | 2018-05-09 | Symrise AG | Compositions comprising polyalkylene glycol derivatives |
EP3347445B1 (en) | 2015-09-08 | 2024-10-30 | Symrise AG | Fragrance mixtures |
WO2017071752A1 (en) | 2015-10-28 | 2017-05-04 | Symrise Ag | Method for inhibiting or masking fishy odours |
US10590100B2 (en) | 2015-11-11 | 2020-03-17 | Ambient Photonics, Inc. | Benzofuran derivatives for the treatment of CNS and other disorders |
US12053537B2 (en) | 2015-11-15 | 2024-08-06 | Symrise Ag | Reduction of stinging sensation on skin |
WO2017097434A1 (en) | 2015-12-06 | 2017-06-15 | Symrise Ag | A fragrance composition |
EP3435969A1 (en) | 2016-03-30 | 2019-02-06 | Symrise AG | An active mixture |
WO2018036625A1 (en) | 2016-08-20 | 2018-03-01 | Symrise Ag | A preservative mixture |
CN110149795B (zh) | 2016-12-02 | 2023-10-03 | 西姆莱斯股份公司 | 化妆品混合物 |
FR3061002B1 (fr) | 2016-12-23 | 2019-05-24 | L'oreal | Composition comprenant de l’acide hydroxyethylpiperazine ethane sulfonique et au moins un alkylpolyglucoside |
IT201700090929A1 (it) | 2017-08-07 | 2019-02-07 | Cutech S R L | Usi cosmetici e medici di estratti del fungo Coprinus comatus per la regolazione dell’unità pilo sebacea. |
EP3664772B1 (en) | 2017-08-09 | 2024-03-20 | Symrise AG | 1,2-alkanediols and a process for their production |
DE202017007679U1 (de) | 2017-08-09 | 2024-03-15 | Symrise Ag | 1,2-Alkandiole |
EP3813795A1 (en) | 2018-03-08 | 2021-05-05 | Symrise AG | Mixtures comprising a protein extract for the treatment of human skin and/or hair |
WO2020057761A1 (en) | 2018-09-20 | 2020-03-26 | Symrise Ag | Compositions comprising odorless 1,2-pentanediol |
WO2020182318A1 (en) | 2019-03-12 | 2020-09-17 | Symrise Ag | An antimicrobial mixture |
PL4096618T3 (pl) | 2020-12-09 | 2025-08-11 | Symrise Ag | Mieszanina zawierająca 1,2-alkanodiole |
FR3126311B1 (fr) | 2021-08-27 | 2024-12-20 | Oreal | Procede cosmetique non therapeutique pour reduire les rides sur une surface de la peau, kit pour la mise en œuvre du procede, et procede d’utilisation d’un kit |
WO2023286879A2 (en) | 2021-07-16 | 2023-01-19 | L'oreal | A non-therapeutic cosmetic method for reducing wrinkles on a skin surface, a kit for implementing the method, and a method of using a kit |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188486A (en) * | 1976-12-07 | 1980-02-12 | Kanebo, Ltd. | 2-Substituted benzimidazole compounds |
EP0098448A2 (de) * | 1982-07-01 | 1984-01-18 | Dr. Karl Thomae GmbH | Neue Imidazolderivate, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE676103C (de) * | 1933-03-31 | 1939-05-25 | I G Farbenindustrie Akt Ges | Strahlungsschutzmittel |
GB846737A (en) * | 1956-04-19 | 1960-08-31 | Merck & Co Inc | 3-substituted 4-hydroxybenzoic acids and their preparation |
CH483276A (de) * | 1959-09-23 | 1969-12-31 | Ciba Geigy | Verwendung von 2-Phenyl-benzazolen als Schutzmittel vor ultravioletter Strahlung ausserhalb der Textilindustrie |
GB1067575A (en) * | 1963-06-28 | 1967-05-03 | Jacques Logeais Soc D Expl Des | Therapeutic compositions containing phloroglucinol derivatives, new derivatives of phloroglucinol and process for preparing the same |
IL23847A (en) * | 1964-08-07 | 1969-02-27 | Merck & Co Inc | Benzimidazoles useful as antifungals |
FR1494097A (fr) * | 1965-04-06 | 1967-09-08 | Ciba Geigy | Dérivés du 2-phénylbenzoxazol servant d'agents d'absorption des rayons ultraviolets pour des produits cosmétiques |
DE1642090A1 (de) * | 1966-05-20 | 1971-05-19 | Merck Patent Gmbh | UV-Lichtschutzmittel fuer kosmetische Zwecke |
CH495756A (de) * | 1968-06-11 | 1970-09-15 | Ciba Geigy | Verwendung von neuen, Alkylsulfonsäuregruppen enthaltenden 2-Phenylbenzoxazol-Derivaten als Ultraviolett-Absorber für kosmetische Zwecke |
US3551443A (en) * | 1968-10-30 | 1970-12-29 | Ciba Ltd | 2-phenylbenzoxazole derivatives |
CH523909A (de) * | 1969-01-09 | 1972-06-15 | Ciba Geigy Ag | Verfahren zur Herstellung heterocyclischer, Aethylendoppelbindungen enthaltender Verbindungen und deren Verwendung als optische Aufhellmittel ausserhalb der Textilindustrie |
CH516339A (de) * | 1969-03-03 | 1971-12-15 | Ciba Geigy Ag | Verwendung von Azolverbindungen als Antioxydantien |
DE2419728A1 (de) * | 1974-04-24 | 1975-11-20 | Hoechst Ag | Kosmetisches lichtschutzmittel |
LU71012A1 (en]) * | 1974-09-26 | 1976-08-19 | ||
DE2619547A1 (de) * | 1976-05-04 | 1977-11-24 | Dynamit Nobel Ag | Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen |
US4192880A (en) * | 1977-04-07 | 1980-03-11 | Kanebo, Ltd. | 2-Substituted benzimidazole compounds |
DE3003540A1 (de) * | 1980-01-31 | 1981-08-06 | Bayer Ag, 5090 Leverkusen | Benzoxazolylstilbene, verfahren zu deren herstellung und deren verwendung als optische aufheller |
DD150059A1 (de) * | 1980-04-07 | 1981-08-12 | Horst Hartmann | Verfahren zur herstellung von hydroxyarylazolen |
US4456618A (en) * | 1982-10-15 | 1984-06-26 | Sri International | Naphthenic and heterocyclic retinoic acid analogues |
DE3346575A1 (de) * | 1983-12-23 | 1985-07-04 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel |
CA1281325C (en) * | 1984-06-20 | 1991-03-12 | Patrice C. Belanger | Benzofuran derivatives |
DE3522230A1 (de) * | 1985-06-21 | 1987-01-02 | Thomae Gmbh Dr K | Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3528032A1 (de) * | 1985-08-05 | 1987-02-05 | Hoechst Ag | Verfahren zur herstellung 2-substituierter benzthiazole |
-
1984
- 1984-09-19 LU LU85544A patent/LU85544A1/fr unknown
-
1985
- 1985-09-16 SE SE8504291A patent/SE461466B/xx not_active IP Right Cessation
- 1985-09-16 PT PT81132A patent/PT81132B/pt unknown
- 1985-09-17 FR FR8513747A patent/FR2570377B1/fr not_active Expired
- 1985-09-18 DK DK423285A patent/DK169475B1/da not_active IP Right Cessation
- 1985-09-18 CH CH4050/85A patent/CH665841A5/fr not_active IP Right Cessation
- 1985-09-18 AU AU47559/85A patent/AU578310B2/en not_active Expired
- 1985-09-18 NL NL8502557A patent/NL192878C/nl not_active IP Right Cessation
- 1985-09-18 BE BE0/215596A patent/BE903254A/fr not_active IP Right Cessation
- 1985-09-18 GR GR852270A patent/GR852270B/el unknown
- 1985-09-18 ES ES547750A patent/ES8608487A1/es not_active Expired
- 1985-09-18 CA CA000491026A patent/CA1256804A/fr not_active Expired
- 1985-09-18 AT AT0271885A patent/AT395714B/de not_active IP Right Cessation
- 1985-09-18 DE DE3546907A patent/DE3546907C2/de not_active Expired - Lifetime
- 1985-09-18 JP JP60207724A patent/JPH0784437B2/ja not_active Expired - Fee Related
- 1985-09-18 AR AR85301653A patent/AR243504A1/es active
- 1985-09-18 ZA ZA857158A patent/ZA857158B/xx unknown
- 1985-09-18 IT IT8522180A patent/IT1209663B/it active
- 1985-09-18 DE DE3533308A patent/DE3533308C2/de not_active Expired - Lifetime
- 1985-09-18 CH CH965/88A patent/CH675241A5/fr not_active IP Right Cessation
- 1985-09-18 CA CA000491024A patent/CA1256862A/fr not_active Expired
- 1985-09-19 GB GB8523203A patent/GB2164648B/en not_active Expired
- 1985-10-01 MX MX009009A patent/MX166783B/es unknown
-
1986
- 1986-03-13 US US06/839,269 patent/US4740519A/en not_active Expired - Lifetime
- 1986-03-14 BE BE0/216415A patent/BE904421A/fr not_active IP Right Cessation
- 1986-09-22 AU AU62995/86A patent/AU593838B2/en not_active Expired
-
1987
- 1987-09-30 GB GB878722903A patent/GB8722903D0/en active Pending
- 1987-11-27 GB GB8727803A patent/GB2197320B/en not_active Expired
-
1988
- 1988-03-16 SE SE8800949A patent/SE502470C2/sv not_active IP Right Cessation
- 1988-03-24 US US07/172,494 patent/US4920140A/en not_active Expired - Lifetime
-
1989
- 1989-11-02 US US07/430,286 patent/US5059621A/en not_active Expired - Lifetime
-
1992
- 1992-03-05 AT AT0042192A patent/AT401514B/de not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188486A (en) * | 1976-12-07 | 1980-02-12 | Kanebo, Ltd. | 2-Substituted benzimidazole compounds |
EP0098448A2 (de) * | 1982-07-01 | 1984-01-18 | Dr. Karl Thomae GmbH | Neue Imidazolderivate, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT395714B (de) | Verfahren zur herstellung von neuen aromatischen heterocyclischen verbindungen | |
DE3685528T2 (de) | Aromatische polycyclische derivate, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen und kosmetischen zubereitungen. | |
AT394362B (de) | Verfahren zur herstellung von neuen 2,6-disubstituierten naphthalin-derivaten | |
DE3531722C2 (de) | Benzonorbornen-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende, pharmazeutische und kosmetische Mittel | |
DE3708060C2 (de) | Aromatische Benzopyranyl- und Benzothiopyranyl-Verbindungen, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel und kosmetische Zubereitungen | |
DE3690187C2 (de) | Naphthalinderivate mit retinoider Wirkung, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische und kosmetische Mittel | |
DE3534564C2 (de) | Naphthalinderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische und kosmetische Mittel | |
DE69718734T2 (de) | Bicyclisch-aromatische Verbindungen | |
DE3711546C2 (de) | Aromatische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische und kosmetische Zubereitungen | |
DE69605525T2 (de) | Biaromatische Verbindungen mit Adamantylgruppe in para-Stellung, pharmazeutische und kosmetische Zusammensetzungen, die diese enthalten, und Verwendungen | |
DE3707245C2 (de) | 2,3,4,4a-Tetrahydro-4a,10,10-trimethyl - 1H-3, 9b - methandibenzofuranderivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische und kosmetische Mittel, die diese Verbindungen enthalten | |
DE69402047T2 (de) | Neue von Amiden abgeleitete biaromatische Verbinungen, pharmazeutische und kosmetische Zusammensetzungen, die sie enthalten, und ihre Verwendungen | |
DE69804205T2 (de) | Bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammenstellungen | |
DE60013947T2 (de) | (Poly)thia-alkin-Verbindungen und ihre Derivate, diese enthaltende Zusammensetzungen und ihre Anwendung | |
DE69232270T2 (de) | Benzimidazol-derivate, verfahren zu ihrer herstellung und ihre anwendung in den gebieten therapeutik und kosmetik | |
DE3717389B4 (de) | Neue naphthylaromatische Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung in der Human- und Veterinärmedizin und in der Kosmetik | |
DE68915094T2 (de) | Benzofuranverbindungen, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische und kosmetische Zusammenstellungen und Verwendung dieser Zusammenstellungen. | |
DE69513268T2 (de) | Aromatische Dibenzofuranderivate, sie enthaltende pharmazeutische und kosmetische Zusammenstellungen | |
DE69704213T2 (de) | Bioaromatische dibenzofuranderivate und verwendung in der human- oder tiermedizin und in der kosmetik | |
EP0009777B1 (de) | Retinsäure- und 7,8-Dehydro-retinsäure-N-(carboxy)-phenyl-amide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
DE2502967A1 (de) | Carbonsaeuren, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0009776B1 (de) | N-Monohydroxypropylamide, N-Dihydroxypropylamide und deren Acetonoide der all-E- und 13-Z-Retinsäure, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
DE3605309C2 (de) | Ungesättigte cycloaliphatische Derivate und diese enthaltende pharmazeutische und kosmetische Zusammensetzungen | |
DE3445712C2 (en]) | ||
WO1994006748A1 (de) | Neue in 10-stellung substituierte anthron- und anthracen-derivate, verfahren zu deren herstellung, diese verbindungen enthaltende pharmazeutische oder kosmetische mittel und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ELJ | Ceased due to non-payment of the annual fee |